

Microsoft Bing	Real world evidence on first and second line palliative chemothera			Q.	Q
	ALL IMAGES	VIDEOS			

Real World Evidence on Second-Line Palliative Chemotherapy ...

Real World Evidence on Second-Line Palliative Chemotherapy ...

https://pubmed.ncbi.nlm.nih.gow/32850339

Background The outcome and tolerability of palliative second line chemotherapy for advanced pancreatic cancer (APC) in real life patients are largely unknown. Prognostic parameters for risk statification and treatment guidance are lacking. Materials and Methods: A population based multice retrospective cohort study was conducted, covering all APC patients who received palliative second.

Cited by: 1 Author: Emma Gränsmark, Nellie Bägenholm Bylin, ...
Publish Year: 2020

146,000 Résults Any time +

Frontiers | Real World Evidence on Second-Line Palliative ...

https://www.frontiersin.org/articles/10.3389/fonc.2020.01176 +

Jul 27, 2020 - Results: A total of 509 patients received first-line palliative chemotherapy, and of these 167
(33%) received at least one dose of second-line therapy and formed the final study population. Median
0S2 was 5.2 months (95% CI = 4.7-5.7) and median TTF2 was 1.9 months (1.5-2.2).


Cited by: 1 Author: Emma Gränsmark, Nellie Bågenholm Bylin, ...
Publish Year: 2020

PEOPLE ALSO ASK	
Are there any second line therapies for pancreatic cancer?	V
Which is the first treatment for pancreatic cancer?	V
When did erlotinib stop being used for pancreatic cancer?	V
What is the 5 year survival rate for pancreatic cancer?	~
	Promoto

Real world evidence on gemcitabine and nab ... - BMC Cancer https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-5244-2 - Jan 08, 2019 - This study confirms the effectiveness and safety of first-line Gem/NabP in both locally advanced and metastatic POA in a real world setting, in the recent phase ill trial hiPACT the combination of gemcitabine and nab-pacitiaxel (Gem/NabP) showed increased overall survival compared to gemcitabine alone in the treatment of advanced pancreatic ductal adenocarcinoma (aPOA). Cited by: 23 — Author-Hakon Ellomatrand, Ursula Schebling, Char...
Publish Year; 2019 — Estimated Reading Time: 11 mins

Search Tools

Turn off Hover Translation (美团取调)



Real world evidence on first and second line palliative chemotheral

:::I



Q

ALL

IMAGES

VIDEOS

133,000 Results

Any time ▼

Real World Evidence on Second-Line Palliative ...

https://pubmed.ncbi.nlm.nih.gov/32850339

Background: The outcome and tolerability of palliative second line chemotherapy for advanced pancreatic cancer (APC) in real life patients are largely unknown. Prognostic parameters for risk stratification and treatment guidance are lacking. Materials and Methods: A population based multicenter retrospective cohort study was conducted, covering all APC patients who received palliative second ...

Cited by: 1 Author: Emma Gränsmark, Nellie Bågenholm Byli...

Publish Year: 2020

Frontiers | Real World Evidence on Second-Line Palliative ...

https://www.frontiersin.org/articles/10.3389/fonc.2020.01176 •

Jul 27, 2020 · Results: A total of 509 patients received **first-line palliative chemotherapy**, and of these 167 (33%) received at least one dose of **second-line therapy** and formed the final study population. Median OS2 was 5.2 months (95% CI = 4.7-5.7) and median TTF2 was 1.9 months (1.5-2.2).

Cited by: 1 Author: Emma Gränsmark, Nellie Bågenholm Byli...

Publish Year: 2020



Feedback

Real world evidence on gemcitabine and nab ... - BMC Cancer

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-5244-2 •

Jan 08, 2019 · This study confirms the effectiveness and safety of first-line Gem/NabP in both locally advanced and metastatic PDA in a real world setting. In the recent phase III trial MPACT the combination of gemcitabine and nab-paclitaxel (Gem/NabP) showed increased overall survival compared